Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$130.63K-$130.63KN/M vs Q3 2023 EPS Diluted$0.00$0.00N/M vs Q3 2023 Operating Income-$152,278N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
derived
ended May 31, 2024 · filed Jul 15, 2024 · 45 d after period end